Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the administration of omega-3
polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to
reduce coronary artery disease (CAD) risk and illness severity in clinically-stable patients
with schizophrenia (or schizoaffective disorder), major depression or bipolar disorder
(depressed phase) being treated with lipid lowering drugs (e.g., statins).
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
American Heart Association VA Pittsburgh Healthcare System